ZA200210224B - Topical pharmaceutical formulations and methods of treatment. - Google Patents
Topical pharmaceutical formulations and methods of treatment. Download PDFInfo
- Publication number
- ZA200210224B ZA200210224B ZA200210224A ZA200210224A ZA200210224B ZA 200210224 B ZA200210224 B ZA 200210224B ZA 200210224 A ZA200210224 A ZA 200210224A ZA 200210224 A ZA200210224 A ZA 200210224A ZA 200210224 B ZA200210224 B ZA 200210224B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical formulation
- formulation
- therapeutic agent
- skin
- carrier medium
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 94
- 238000000034 method Methods 0.000 title claims description 63
- 230000000699 topical effect Effects 0.000 title claims description 6
- 239000000203 mixture Substances 0.000 claims description 89
- 239000003814 drug Substances 0.000 claims description 77
- 229940124597 therapeutic agent Drugs 0.000 claims description 75
- 238000009472 formulation Methods 0.000 claims description 57
- 230000000694 effects Effects 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 13
- 238000011200 topical administration Methods 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- 230000002500 effect on skin Effects 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000003246 corticosteroid Substances 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 229940127557 pharmaceutical product Drugs 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 230000003444 anaesthetic effect Effects 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims description 2
- 206010040872 skin infection Diseases 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims 13
- 238000007493 shaping process Methods 0.000 claims 13
- 235000014113 dietary fatty acids Nutrition 0.000 claims 6
- 239000000194 fatty acid Substances 0.000 claims 6
- 229930195729 fatty acid Natural products 0.000 claims 6
- 150000004665 fatty acids Chemical class 0.000 claims 5
- 239000008187 granular material Substances 0.000 claims 5
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 5
- 239000007909 solid dosage form Substances 0.000 claims 5
- 238000003892 spreading Methods 0.000 claims 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 4
- 229940110456 cocoa butter Drugs 0.000 claims 4
- 235000019868 cocoa butter Nutrition 0.000 claims 4
- 238000001816 cooling Methods 0.000 claims 4
- -1 polyoxyethylene Polymers 0.000 claims 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 238000005056 compaction Methods 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 229960000890 hydrocortisone Drugs 0.000 claims 3
- 229960004194 lidocaine Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical group CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 claims 2
- 239000004166 Lanolin Substances 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 241000219161 Theobroma Species 0.000 claims 2
- 229940121375 antifungal agent Drugs 0.000 claims 2
- 239000003429 antifungal agent Substances 0.000 claims 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims 2
- 229960003150 bupivacaine Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000011109 contamination Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 150000002191 fatty alcohols Chemical class 0.000 claims 2
- 150000002194 fatty esters Chemical class 0.000 claims 2
- 150000002314 glycerols Chemical class 0.000 claims 2
- 150000002334 glycols Chemical class 0.000 claims 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 235000019388 lanolin Nutrition 0.000 claims 2
- 229940039717 lanolin Drugs 0.000 claims 2
- 239000003589 local anesthetic agent Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 239000003921 oil Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 229960002372 tetracaine Drugs 0.000 claims 2
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 claims 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims 1
- OGQYJDHTHFAPRN-UHFFFAOYSA-N 2-fluoro-6-(trifluoromethyl)benzonitrile Chemical compound FC1=CC=CC(C(F)(F)F)=C1C#N OGQYJDHTHFAPRN-UHFFFAOYSA-N 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 1
- 239000004342 Benzoyl peroxide Substances 0.000 claims 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims 1
- 206010012444 Dermatitis diaper Diseases 0.000 claims 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000005864 Sulphur Substances 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 230000037374 absorbed through the skin Effects 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 229960000552 alclometasone Drugs 0.000 claims 1
- DJHCCTTVDRAMEH-DUUJBDRPSA-N alclometasone dipropionate Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DJHCCTTVDRAMEH-DUUJBDRPSA-N 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims 1
- 229940083916 aluminum distearate Drugs 0.000 claims 1
- RDIVANOKKPKCTO-UHFFFAOYSA-K aluminum;octadecanoate;hydroxide Chemical compound [OH-].[Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O RDIVANOKKPKCTO-UHFFFAOYSA-K 0.000 claims 1
- 229960003099 amcinonide Drugs 0.000 claims 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 claims 1
- 229960003204 amorolfine Drugs 0.000 claims 1
- 229940124326 anaesthetic agent Drugs 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000002421 anti-septic effect Effects 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- 235000013871 bee wax Nutrition 0.000 claims 1
- 239000012166 beeswax Substances 0.000 claims 1
- 229940092738 beeswax Drugs 0.000 claims 1
- 239000000440 bentonite Substances 0.000 claims 1
- 229910000278 bentonite Inorganic materials 0.000 claims 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims 1
- 229960005274 benzocaine Drugs 0.000 claims 1
- 235000019400 benzoyl peroxide Nutrition 0.000 claims 1
- 229960003328 benzoyl peroxide Drugs 0.000 claims 1
- 229960002537 betamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 229960002023 chloroprocaine Drugs 0.000 claims 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims 1
- 229960003185 chlortetracycline hydrochloride Drugs 0.000 claims 1
- 229960001747 cinchocaine Drugs 0.000 claims 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims 1
- 229960002842 clobetasol Drugs 0.000 claims 1
- 229960004022 clotrimazole Drugs 0.000 claims 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims 1
- 239000011280 coal tar Substances 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 239000007891 compressed tablet Substances 0.000 claims 1
- 229940124558 contraceptive agent Drugs 0.000 claims 1
- 239000003433 contraceptive agent Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 125000000017 cortisol group Chemical group 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960004154 diflorasone Drugs 0.000 claims 1
- WXURHACBFYSXBI-XHIJKXOTSA-N diflorasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-XHIJKXOTSA-N 0.000 claims 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 claims 1
- 229960002311 dithranol Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229960003913 econazole Drugs 0.000 claims 1
- 229960003976 etidocaine Drugs 0.000 claims 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 1
- 229960000289 fluticasone propionate Drugs 0.000 claims 1
- 229960003704 framycetin Drugs 0.000 claims 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims 1
- 229960004675 fusidic acid Drugs 0.000 claims 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- 229940125697 hormonal agent Drugs 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940027897 ichthammol Drugs 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- WAHQBNXSPALNEA-UHFFFAOYSA-L lithium succinate Chemical compound [Li+].[Li+].[O-]C(=O)CCC([O-])=O WAHQBNXSPALNEA-UHFFFAOYSA-L 0.000 claims 1
- 229960004254 lithium succinate Drugs 0.000 claims 1
- 229960005015 local anesthetics Drugs 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 229960002409 mepivacaine Drugs 0.000 claims 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 1
- 201000003152 motion sickness Diseases 0.000 claims 1
- 229940043348 myristyl alcohol Drugs 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000004033 plastic Substances 0.000 claims 1
- 229920003023 plastic Polymers 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960001807 prilocaine Drugs 0.000 claims 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims 1
- 229960004919 procaine Drugs 0.000 claims 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 1
- 229960004063 propylene glycol Drugs 0.000 claims 1
- 235000013772 propylene glycol Nutrition 0.000 claims 1
- 229960001549 ropivacaine Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940124535 smoking cessation aid Drugs 0.000 claims 1
- 238000007711 solidification Methods 0.000 claims 1
- 230000008023 solidification Effects 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 229960004274 stearic acid Drugs 0.000 claims 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229960001727 tretinoin Drugs 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 229940072358 xylocaine Drugs 0.000 claims 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 17
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 6
- 229960002882 calcipotriol Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 208000037147 Hypercalcaemia Diseases 0.000 description 2
- 210000003027 ear inner Anatomy 0.000 description 2
- 230000000148 hypercalcaemia Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- MHNSPTUQQIYJOT-SJDTYFKWSA-N Doxepin Hydrochloride Chemical compound Cl.C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 MHNSPTUQQIYJOT-SJDTYFKWSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229940075049 dovonex Drugs 0.000 description 1
- 229960002861 doxepin hydrochloride Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 208000037851 severe atopic dermatitis Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0015617.4A GB0015617D0 (en) | 2000-06-26 | 2000-06-26 | Improved preparations for dermal delivery of active substances |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200210224B true ZA200210224B (en) | 2003-06-18 |
Family
ID=9894412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200210224A ZA200210224B (en) | 2000-06-26 | 2002-12-18 | Topical pharmaceutical formulations and methods of treatment. |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US7754240B2 (enExample) |
| EP (2) | EP1296652B1 (enExample) |
| JP (1) | JP2004501185A (enExample) |
| KR (1) | KR20030041871A (enExample) |
| CN (1) | CN1438878A (enExample) |
| AT (1) | ATE429904T1 (enExample) |
| AU (2) | AU2001267686A1 (enExample) |
| BR (1) | BR0112356A (enExample) |
| CA (1) | CA2413699C (enExample) |
| DE (1) | DE60138547D1 (enExample) |
| DK (1) | DK1296652T3 (enExample) |
| ES (1) | ES2325980T3 (enExample) |
| GB (1) | GB0015617D0 (enExample) |
| HU (1) | HUP0301121A3 (enExample) |
| IL (1) | IL153665A0 (enExample) |
| MX (1) | MXPA02012666A (enExample) |
| NO (1) | NO333292B1 (enExample) |
| PL (1) | PL211890B1 (enExample) |
| WO (1) | WO2002000203A1 (enExample) |
| ZA (1) | ZA200210224B (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8188043B2 (en) * | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| GB2383950B (en) * | 2002-01-11 | 2006-01-18 | Cosmetic Warriors Ltd | Cosmetic product |
| AU2003223005A1 (en) | 2002-05-06 | 2003-11-17 | Vectura Limited | Application device for topical administration of pharmaceutical agents |
| US20070065463A1 (en) | 2003-06-20 | 2007-03-22 | Ronald Aung-Din | Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions |
| US7718674B2 (en) * | 2004-09-27 | 2010-05-18 | Bridge Pharma, Inc. | Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine |
| DE102004059613A1 (de) * | 2004-12-10 | 2006-06-14 | Liedtke, Rainer K., Dr. | Zusammensetzung und Methode einer topischen Therapie von Neurodermitis |
| GB0524961D0 (en) * | 2005-12-07 | 2006-01-18 | Pharmakodex Ltd | Transdermal administration of active agents for systemic effect |
| GB0524959D0 (en) * | 2005-12-07 | 2006-01-18 | Pharmakodex Ltd | Topical compositions for treatment of respiratory disorders |
| US20090215753A1 (en) * | 2005-12-07 | 2009-08-27 | Pharmacodex Ltd. | Topical Compositions for Paediatric Use |
| EP2206494B1 (en) | 2006-03-31 | 2015-12-02 | Stiefel Research Australia Pty Ltd | Foamable suspension gel |
| GB0612556D0 (en) * | 2006-06-23 | 2006-08-02 | Univ Aston | Topical pharmaceutical formulations |
| US20090221703A1 (en) * | 2006-07-09 | 2009-09-03 | Chongxi Yu | High penetration composition and uses thereof |
| WO2008011161A2 (en) * | 2006-07-21 | 2008-01-24 | Bridge Pharma, Inc. | Dermal anesthetic compounds |
| US20080287373A1 (en) * | 2007-05-17 | 2008-11-20 | Popp Karl F | Topical skin treating kits |
| GB2450117A (en) * | 2007-06-13 | 2008-12-17 | Reckitt Benckiser Healthcare | A water- and oxygen-occlusive blister tablet pack |
| CA2689472C (en) * | 2008-07-18 | 2019-01-15 | Karine Theberge | Articles of manufacture releasing an active ingredient |
| ES2400210T3 (es) | 2008-10-02 | 2013-04-08 | Mylan Inc. | Método para preparar un laminado de adhesivo multicapa |
| JP5913095B2 (ja) | 2009-06-26 | 2016-04-27 | タリス バイオメディカル エルエルシー | 植込み型薬物送達装置及びその作製方法 |
| US8470304B2 (en) | 2009-08-04 | 2013-06-25 | Avidas Pharmaceuticals Llc | Therapeutic vitamin D sun-protecting formulations and methods for their use |
| US9017312B2 (en) | 2009-09-10 | 2015-04-28 | Taris Biomedical Llc | Implantable device for controlled drug delivery |
| EP2593185A1 (en) | 2010-07-17 | 2013-05-22 | Merck Patent GmbH | Enhancement of penetration and action |
| EP2441444A1 (en) * | 2010-10-14 | 2012-04-18 | Deva Holding Anonim Sirketi | Formulations of cetyl myristate and/or cetyl palmitate |
| SG189350A1 (en) | 2010-10-15 | 2013-05-31 | Procter & Gamble | Use of monoamine oxidase inhibitors to improve epithelial biology |
| US8293288B2 (en) | 2011-02-23 | 2012-10-23 | Edna Ma | Pain relieving composition |
| US8512768B2 (en) | 2011-02-23 | 2013-08-20 | Miss Smarty Pants Enterprises, Inc. | Pain relieving composition |
| MX368747B (es) | 2011-05-10 | 2019-10-14 | Itochu Chemical Frontier Corp | Parche no acuoso de lidocaína y un agente de disolución que comprende un ácido orgánico y un polialcohol que están contenidos en un emplaste para usarse en el tratamiento de dolor muscular a través de la piel. |
| US11786455B2 (en) | 2011-05-10 | 2023-10-17 | Itochu Chemical Frontier Corporation | Non-aqueous patch |
| ES3034911T3 (en) | 2011-05-10 | 2025-08-26 | Itochu Chemical Frontier Corp | Non-aqueous patch |
| SI2823815T1 (sl) | 2011-09-27 | 2018-09-28 | Itochu Chemical Frontier Corporation | Ne-vodni obliž |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| CN102641275B (zh) * | 2012-05-16 | 2013-04-24 | 江苏圣宝罗药业有限公司 | 复方丙酸氯倍他索与维a酸软膏剂 |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| KR20150119468A (ko) | 2013-02-28 | 2015-10-23 | 더미라, 인코포레이티드 | 글리코피롤레이트 염 |
| US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
| US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
| CA2903020C (en) * | 2013-02-28 | 2019-06-18 | Mira Pharma Corporation | Injectable long-acting local anesthetic semi-solid formulations and its compostions |
| US10220093B2 (en) | 2013-02-28 | 2019-03-05 | Mira Pharma Corporation | Long-acting semi-solid lipid formulations |
| JP6517186B2 (ja) | 2013-03-15 | 2019-05-22 | タリス バイオメディカル エルエルシー | 薬物透過性構成部材を備えた薬物送達デバイス、及び方法 |
| WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| CA2919215C (en) | 2013-08-19 | 2022-11-29 | Taris Biomedical Llc | Multi-unit drug delivery devices and methods |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| AU2015290098B2 (en) | 2014-07-17 | 2018-11-01 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| AU2015296609A1 (en) | 2014-07-29 | 2016-12-22 | Therapeuticsmd, Inc. | Transdermal cream |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| EP3273940B1 (en) | 2015-03-23 | 2020-12-16 | Biopharmx, Inc. | Pharmaceutical tetracycline composition for dermatological use |
| US10894150B2 (en) | 2015-04-23 | 2021-01-19 | Taris Biomedical Llc | Drug delivery devices with drug-permeable component and methods |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| US11426418B2 (en) | 2017-12-06 | 2022-08-30 | Mira Pharma Corporation | Injectable long-acting semi-solid gel formulations |
| US10561606B2 (en) | 2017-12-06 | 2020-02-18 | Mira Pharma Corporation | Injectable long-acting local anesthetic semi-solid gel formulations |
| CN108853140A (zh) * | 2018-07-18 | 2018-11-23 | 豆立忠 | 一种多药物模块软膏及其制备方法 |
| WO2020049505A1 (en) | 2018-09-06 | 2020-03-12 | Innopharmascreen Inc. | Methods and compositions for treatment of asthma or parkinson's disease |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| CN112237547B (zh) * | 2020-09-28 | 2022-08-30 | 安徽美邸康药业有限公司 | 一种药贴成型装置 |
| MX2020011523A (es) * | 2020-10-29 | 2022-05-02 | Exeltis Pharma Mexico S A De C V | Composicion farmaceutica adecuada para administracion vaginal en forma de ovulos y uso de la misma. |
| BE1028968B1 (nl) | 2020-12-29 | 2022-08-01 | Usocore Nv | Harde was zonder BHT |
| WO2024064151A1 (en) * | 2022-09-21 | 2024-03-28 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic stimulation of mucociliary clearance to treat mucus obstruction in cystic fibrosis and other muco-obstructive disorders |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US369784A (en) * | 1887-09-13 | fueman | ||
| US308343A (en) * | 1884-11-25 | Pail handle | ||
| US151274A (en) * | 1874-05-26 | Improvement in springs for vehicles | ||
| US597849A (en) * | 1898-01-25 | Ditching-jack | ||
| US765986A (en) * | 1902-06-07 | 1904-07-26 | Nat Tube Co | Conical rolls for piercing, expanding, or cross-rolling metal billets or tubular blanks. |
| US863941A (en) * | 1906-06-05 | 1907-08-20 | James M Robbins | Wheelwright-machine. |
| US892890A (en) * | 1907-10-14 | 1908-07-07 | Max A Repelow | Card-index. |
| AU513753B2 (en) * | 1974-07-08 | 1980-12-18 | Johnson & Johnson | Antimicrobial composition |
| DE2551446B2 (de) * | 1975-11-15 | 1977-09-15 | Karl Werner Schlüter GmbH, 2000 Ham burg | Verfahren zur herstellung von suppositorien |
| CH637014A5 (de) * | 1978-09-29 | 1983-07-15 | Sandoz Ag | Verfahren zur herstellung von suppositorien. |
| DE2920500A1 (de) * | 1979-05-21 | 1980-11-27 | Boehringer Sohn Ingelheim | Pharmazeutische zubereitung in form eines polyacrylatfilmes |
| US4278679A (en) * | 1980-05-01 | 1981-07-14 | Chromalloy American Corporation | Combination of two or more drugs in a single dosage form wherein one of the drugs is a physostigmine compound |
| FR2515036B1 (fr) * | 1981-10-23 | 1986-12-05 | Oreal | Composition stable a l'oxydation d'anthraline ou de l'un de ses derives et son utilisation dans le traitement des maladies de la peau |
| US4495203A (en) | 1981-10-23 | 1985-01-22 | Societe Anonyme Dite: L'oreal | Anhydrous composition, stable to oxidation, based on anthralin or one of its derivatives, in a carrier consisting of a fatty acid alkyl ester and a thickener, and its use in the treatment of skin diseases |
| US4892890A (en) * | 1984-11-01 | 1990-01-09 | G. D. Searle And Company | External analgesic compositions |
| DE3522060A1 (de) * | 1985-06-20 | 1987-01-08 | Liedtke Pharmed Gmbh | Arzneipflaster fuer systemische anwendungen |
| DE3523454A1 (de) * | 1985-07-01 | 1987-01-08 | Eberhard Prof Dr Nuernberg | Formkoerper |
| US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| FR2633187A1 (fr) | 1988-06-23 | 1989-12-29 | Gafner Paul Felix | Dispositif applicateur cutane d'une solution medicamenteuse pour le traitement dermatologique |
| AU622961B2 (en) * | 1988-12-23 | 1992-04-30 | Westech Industrial Ltd. | Flame arrester having detonation-attenuating means |
| LU87416A1 (fr) * | 1988-12-29 | 1990-07-10 | Cird | Microgranules charges en une substance active,constitues essentiellement d'un triglyceride d'acides gras satures et leur utilisation par voie topique dans le domaine therapeutique |
| US5389686A (en) * | 1989-02-20 | 1995-02-14 | Jouveinal Sa | Analgesic properties of fedotozine |
| FR2663007A1 (fr) | 1990-06-08 | 1991-12-13 | Kodak Pathe | Emballage de produits photographiques en bandes. |
| US5121158A (en) * | 1990-10-31 | 1992-06-09 | Umax Data System Inc. | Filter driving mechanism for color optical reader |
| JP3086290B2 (ja) * | 1991-07-26 | 2000-09-11 | エスエス製薬株式会社 | ジクロフェナクナトリウム貼付剤 |
| JPH07258071A (ja) * | 1994-03-22 | 1995-10-09 | Ojiro Yukagaku Kenkyusho:Kk | 粒状皮膚用剤およびその用途 |
| US5597849A (en) * | 1994-11-14 | 1997-01-28 | Medical Polymer Technologies, Inc. | Stick formulations for topical drug delivery of therapeutic agents and uses thereof |
| US5785991A (en) * | 1995-06-07 | 1998-07-28 | Alza Corporation | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
| DE19524691A1 (de) * | 1995-07-06 | 1997-01-09 | Liedtke Pharmed Gmbh | Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen |
| US5722424A (en) * | 1995-09-29 | 1998-03-03 | Target Therapeutics, Inc. | Multi-coating stainless steel guidewire |
| JPH09169635A (ja) * | 1995-12-20 | 1997-06-30 | Sekisui Chem Co Ltd | 経皮吸収製剤 |
| GB9611356D0 (en) * | 1996-05-31 | 1996-08-07 | Howard Alan N | Improvements in or relating to compositions containing Creatine, and other ergogenic compounds |
| DE69926017T2 (de) * | 1998-04-27 | 2005-12-22 | SurModics, Inc., Eden Prairie | Bioaktive Wirkstoffe freisetzende Beschichtungen |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6325807B1 (en) * | 1999-06-11 | 2001-12-04 | Scimed Life Systems, Inc. | Variable strength sheath |
| US6455066B1 (en) * | 2000-03-10 | 2002-09-24 | Epicept Corporation | Intradermal-penetration agents for topical local anesthetic administration |
| US6517520B2 (en) * | 2000-12-21 | 2003-02-11 | Ethicon Endo Surgery, Inc. | Peripherally inserted catheter with flushable guide-tube |
-
2000
- 2000-06-26 GB GBGB0015617.4A patent/GB0015617D0/en not_active Ceased
-
2001
- 2001-06-26 EP EP01945471A patent/EP1296652B1/en not_active Expired - Lifetime
- 2001-06-26 KR KR1020027017591A patent/KR20030041871A/ko not_active Withdrawn
- 2001-06-26 BR BR0112356-4A patent/BR0112356A/pt not_active Application Discontinuation
- 2001-06-26 HU HU0301121A patent/HUP0301121A3/hu unknown
- 2001-06-26 EP EP07122565A patent/EP2027851A1/en not_active Withdrawn
- 2001-06-26 CA CA2413699A patent/CA2413699C/en not_active Expired - Fee Related
- 2001-06-26 DK DK01945471T patent/DK1296652T3/da active
- 2001-06-26 IL IL15366501A patent/IL153665A0/xx not_active IP Right Cessation
- 2001-06-26 AT AT01945471T patent/ATE429904T1/de active
- 2001-06-26 MX MXPA02012666A patent/MXPA02012666A/es active IP Right Grant
- 2001-06-26 US US10/312,475 patent/US7754240B2/en not_active Expired - Fee Related
- 2001-06-26 AU AU2001267686A patent/AU2001267686A1/en not_active Abandoned
- 2001-06-26 DE DE60138547T patent/DE60138547D1/de not_active Expired - Lifetime
- 2001-06-26 ES ES01945471T patent/ES2325980T3/es not_active Expired - Lifetime
- 2001-06-26 WO PCT/GB2001/002823 patent/WO2002000203A1/en not_active Ceased
- 2001-06-26 JP JP2002504985A patent/JP2004501185A/ja not_active Ceased
- 2001-06-26 CN CN01811778A patent/CN1438878A/zh active Pending
- 2001-06-26 PL PL360868A patent/PL211890B1/pl not_active IP Right Cessation
-
2002
- 2002-12-18 ZA ZA200210224A patent/ZA200210224B/en unknown
- 2002-12-20 NO NO20026171A patent/NO333292B1/no not_active IP Right Cessation
-
2006
- 2006-06-09 AU AU2006202479A patent/AU2006202479C1/en not_active Ceased
-
2008
- 2008-03-19 US US12/077,331 patent/US20080166413A1/en not_active Abandoned
-
2010
- 2010-07-08 US US12/832,907 patent/US8158613B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200210224B (en) | Topical pharmaceutical formulations and methods of treatment. | |
| Garg et al. | Comprehensive review on additives of topical dosage forms for drug delivery | |
| CA2931144C (en) | Anti-infective methods, compositions, and devices | |
| US7927034B2 (en) | Application device for topical administration of pharmaceutical compositions and products | |
| JP2009518375A (ja) | 局所医薬組成物 | |
| HUP0302881A2 (hu) | Legalább egy D-vitamint vagy D-vitamin analóg vegyületet és legalább egy kortikoszteroidot tartalmazó külsőleges gyógyszerkészítmények | |
| AU1841200A (en) | Anhydrous topical skin preparations | |
| CA2613221A1 (en) | Topical skin treating compositions | |
| EP2373305B1 (en) | Transdermal pharmaceutical compositions comprising a serm | |
| EP0784975B1 (en) | Use of acetylsalicylic acid in the manufacture of a drug for the treatment of skin injuries | |
| JPH10511653A (ja) | カルシトリオール代謝の阻害剤としてのベンゾイミダゾール類 | |
| US20150182630A1 (en) | Hydrogel composition for the treatment of dermatological disorders | |
| HK1128875A (en) | Topical pharmaceutical formulations and methods of treatment | |
| HK1056311B (en) | Topical pharmaceutical formulations and methods of treatment | |
| HK1242222A1 (en) | Transdermal pharmaceutical compositions comprising a serm | |
| HK1001375B (en) | Use of acetylsalicylic acid in the manufacture of a drug for the treatment of skin injuries | |
| ITMI960656A1 (it) | Uso di contenitori monodose per somministrazioni di formulazioni farmaceutiche ad uso topico (esterno) | |
| HK1242222B (en) | Transdermal pharmaceutical compositions comprising a serm |